Suppr超能文献

垂体放疗的现代技术。

Modern techniques for pituitary radiotherapy.

作者信息

Minniti G, Gilbert D C, Brada M

机构信息

Neuro-oncology Unit, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Surrey, UK.

出版信息

Rev Endocr Metab Disord. 2009 Jun;10(2):135-44. doi: 10.1007/s11154-008-9106-0.

Abstract

Radiotherapy (RT) remains an effective treatment for residual or recurrent pituitary adenomas with excellent rates of tumour control and normalisation of excess hormone secretion. The main late toxicity is hypopituitarism: other side effects are rare. We discuss technical developments in the delivery of radiotherapy (stereotactic conformal radiotherapy (SCRT) and stereotactic radiosurgery (SRS)), all aiming to reduce the amount of normal brain receiving significant doses of radiation. We provide a comprehensive review of published data on outcome of conventional fractionated radiotherapy and modern RT techniques. SCRT is a suitable treatment technique for all sizes of pituitary adenoma and efficacy is comparable to conventional RT; the lack of long term follow up means that currently there is no information on potential reduction in the incidence of late radiation induced toxicity. Single fraction SRS can only be safely delivered to small tumours away from critical structures. There is no evidence that it produces faster decline of elevated hormone levels than fractionated treatment and is not associated with lesser morbidity.

摘要

放射治疗(RT)仍然是治疗残留或复发性垂体腺瘤的有效方法,肿瘤控制率高,过量激素分泌可恢复正常。主要的晚期毒性是垂体功能减退:其他副作用很少见。我们讨论了放射治疗(立体定向适形放射治疗(SCRT)和立体定向放射外科(SRS))技术的发展,所有这些技术都旨在减少接受高剂量辐射的正常脑组织量。我们对已发表的关于传统分次放射治疗和现代放疗技术结果的数据进行了全面综述。SCRT是治疗各种大小垂体腺瘤的合适技术,疗效与传统放疗相当;缺乏长期随访意味着目前尚无关于晚期放射性毒性发生率潜在降低的信息。单次分割SRS只能安全地用于远离关键结构的小肿瘤。没有证据表明它比分次治疗能更快地降低升高的激素水平,也与较低的发病率无关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验